ArticleHuman vaccines & immunotherapeutics2021
Need for hepatitis A prevention in patients with chronic liver disease in the changing epidemiological setting of India.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Hepatitis A virus endemicity and vaccine policy, India.Bulletin of the World Health Organization · 2026Article
- Expert consensus and recommendations on the live attenuated hepatitis A vaccine and immunization practices in India.Human vaccines & immunotherapeutics · 2025Article
- Hepatitis A: A wake-up call!Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Severe acute hepatitis due to hepatitis A virus in adults: Further evidence and a clarion call.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Rising adult hepatitis A in Pakistan: Shifting trends and public health solutions.World journal of virology · 2025Article
- Review
- A Modern Perspective on Vaccinating Healthcare Service Providers in India: A Narrative Review.Infectious diseases and therapy · 2022Review
- Vaccination in Chronic Liver Disease: An Update.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burden of chronic liver disease (CLD) in India is high, particularly among middle-aged men, with nearly 220,000 deaths due to cirrhosis in 2017. CLD increases the risk of infection, severe disease (e.g. hepatitis A virus or HAV superinfection, acute-on-chronic liver failure, fulminant hepatic failure), and mortality. Hence, various countries recommend HAV vaccination for CLD patients. While historic Indian studies showed high seroprevalences of protective HAV antibodies among Indian adults with CLD, the most recent ones found that nearly 7% of CLD patients were susceptible to HAV infection. Studies in healthy individuals have shown that HAV infection in childhood is decreasing in India, resulting in an increasing population of adults susceptible to HAV infection. As patients with CLD are at increased risk of severe HAV infection, now may be the time to recommend HAV vaccination among people with CLD in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.